© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Ampio Pharmaceuticals, Inc. (AMPE) stock remained unchanged at $0.18 a share on OTC. The stock opened at $0.01, fluctuating between $0.01 to $0.18 during the session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 08, 2026 | 0.18 | 0.18 | 0.18 | 0.18 | 372 |
| May 06, 2026 | 0.01 | 0.01 | 0.01 | 0.01 | 166 |
| Apr 28, 2026 | 0.01 | 0.01 | 0.01 | 0.01 | 502 |
| Apr 20, 2026 | 0.30 | 0.30 | 0.01 | 0.25 | 532 |
| Mar 23, 2026 | 0.29 | 0.29 | 0.29 | 0.29 | 150 |
| Mar 20, 2026 | 0.29 | 0.29 | 0.29 | 0.29 | 2K |
| Mar 10, 2026 | 0.28 | 0.28 | 0.28 | 0.28 | 2.67K |
| Nov 06, 2025 | 0.01 | 0.01 | 0.01 | 0.01 | 334 |
| Nov 03, 2025 | 0.01 | 0.01 | 0.01 | 0.01 | 20.71K |
| Oct 27, 2025 | 0.13 | 0.13 | 0.13 | 0.13 | 5.14K |
| Oct 24, 2025 | 0.08 | 0.08 | 0.08 | 0.08 | 1 |
| Oct 23, 2025 | 0.08 | 0.08 | 0.08 | 0.08 | 2 |
| Oct 22, 2025 | 0.08 | 0.08 | 0.08 | 0.08 | 2 |
| Oct 21, 2025 | 0.08 | 0.08 | 0.08 | 0.08 | 18 |
| Oct 20, 2025 | 0.00 | 0.00 | 0.00 | 0.00 | 507 |
| Oct 17, 2025 | 0.08 | 0.08 | 0.08 | 0.08 | 66 |
| Oct 16, 2025 | 0.08 | 0.08 | 0.08 | 0.08 | 1 |
| Oct 14, 2025 | 0.08 | 0.08 | 0.08 | 0.08 | 3 |
| Oct 09, 2025 | 0.08 | 0.08 | 0.08 | 0.08 | 9 |
| Oct 06, 2025 | 0.08 | 0.08 | 0.08 | 0.08 | 1 |
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
| Employees | 6 |
| Beta | 7.78 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |